Approval for the abbott axsym havab 2.0.  The device, as modified, will be marketed under the trade name abbott axsym havab 2.0 and is indicated for the qualitative detection of total antibody to hepatitis a virus (anti-hav) in human serum or plasma.  A test for anti-hav is indicated as an aid in the diagnosis of previous or ongoing hepatitis a viral infection or in the identification of hav-susceptible individuals for vaccination.